Numerous studies have previously reported that 70%–80% of patients with pancreatic adenocarcinoma carry an activating KRAS mutation [67], but the most recent data indicate that mutationally-activated KRAS is present in >90% of patients with pancreatic ductal adenocarcinoma [68,69,70,71], and these discrepancies may be due to variations in the method of KRAS analysis in the different studies. Here, KRAS is linked to pancreatic ductal adenocarcinoma.